⌕
Lexicon Pharmaceuticals · LXRX · Nasdaq
Tenet 41 · Weak
Compare
$1.78+1.71%At closeTenet 41 · Weak
$1.78+0.03 (+1.71%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Lexicon Pharmaceuticals (LXRX) Earnings Forecast

What Wall Street expects this business to earn, and how much analysts disagree.

Sources Analyst estimates EstimatesConsensus as of How we compute thisNot investment advice

16 figures withheld by our checks. Each blank figure names its reason.

Estimates are in the company's reporting currency and are not compared to the USD share price on this page. Filed figures are in US dollars. Nothing here converts between the two.
Consensus as of Nov 16, 2026 · we check it nightly

Analysts expect Lexicon Pharmaceuticals to lose 0.16 a share in FY26 and to earn 0.16 in FY30. 4 analysts publish an estimate for FY26 and 1 for FY30.

Forward P/E · FY26E
Not shown
the estimate and the price are in different currencies
Revisions
Starts tonight
our record of this company begins Nov 16, 2026
Disagreement · FY26
0.03
wide, −0.17 to −0.14
Coverage · FY26
4 · 4
EPS estimates · revenue estimates
Work out what the consensus implies at a multiple you chooseConsensus estimates only. Analysts' price forecasts and ratings are not licensed here.

Are estimates going up or down lately?

We hold no eps window in 90 days for FY26 yet. Every figure here compares one fiscal period at both ends.

No step line for this window yet. A line needs two nights of one fiscal period inside the window to join, and our record does not hold two.

EPS30 days90 daysshown above
FY264 analystsNot yetour record does not hold 30 days of this periodNot yetour record does not hold 90 days of this period
FY274 analystsNot yetour record does not hold 30 days of this periodNot yetour record does not hold 90 days of this period
Dec '263 analystsNot yetour record does not hold 30 days of this periodNot yetour record does not hold 90 days of this period
Mar '272 analystsNot yetour record does not hold 30 days of this periodNot yetour record does not hold 90 days of this period

Measured between two of our own nightly snapshots of one fiscal period, so a new fiscal year entering the view is never read as a revision. Never backfilled. A window still filling says how many days it holds; a blank one means our record is not that long yet.

If the Street is right, what does that imply for the share price?

Price as of close, Nov 16, 2026 · consensus as of Nov 16, 2026

The FY30 consensus is 0.16 a share in the company's reporting currency, and a ratio carries no currency, so a multiple can still be chosen. We stop before the product: it would be a price in the reporting currency, and this share trades in US dollars.

Consensus EBITDA · FY30
0.1B
1 analyst · low 0.1B, high 0.2B · thin coverage
Multiple · EV/EBITDA · yours
No year of positive EBITDA or earnings on record to take a default from, so the multiple can only be yours.
Receipt · LXRX · FY30Nov 16, 2026
Implied, a share
Not computed

We do not convert currencies here. The estimate is in the reporting currency and the share trades in US dollars, so the product would be a price in neither.

Drag the multipleShaded: where Lexicon Pharmaceuticals' P/E sat at each fiscal year end, FY19 to FY19. Each dot is one year.
5×6×8×10×12×

Each point on the line is a multiple, and the flag is the price it implies for FY30. Past multiples are context, not a guide to future ones.

This is multiplication, not a forecast. It assumes the market pays the multiple you chose and that the consensus is right. Both are often wrong.

Not computed across currencies. The consensus is in Lexicon Pharmaceuticals' reporting currency and the share trades in US dollars, so there is no multiple of this year's estimate to set against a growth rate.

How much do analysts disagree?

For FY30, estimates run from 0.08 to 0.25 around an average of 0.16, drawn by 1 analyst.

FY26E4 analysts
−0.17 to −0.14 · 0.03 wide
FY27E4 analysts
−0.24 to −0.17 · 0.07 wide
FY28E5 analysts
−0.19 to 0.09 · 0.28 wide
FY29E1 analyst
0.02 to 0.06 · 0.04 wide
FY30E1 analyst
0.08 to 0.25 · 0.17 wide

A wide spread is disagreement, not risk; a narrow one is agreement, not accuracy. Later years are always wider because fewer people forecast them. Bars in amber rest on fewer than 15 analysts. The tick on each bar is the average. The last filed figure is in US dollars, so it is not placed on this axis. Spreads are shown in currency rather than as percentages, because a percentage of a number near zero overstates it.

Is next quarter a high bar or an easy one?

Analysts expect Lexicon Pharmaceuticals to lose 0.05 a share in the December quarter, the average of 3 estimates. We hold no expected date for the next report.

Expected report
Not held
No expected date is published for this company's next report, so none is printed here.
Revenue expected · December quarter
4,379.2K
3 analysts, 4,379.2 to 4,379.2 in reporting ccy K

For the March quarter, analysts expect a loss of 0.06 a share.

Does Lexicon Pharmaceuticals usually beat or miss?

We have not been able to check a quarter yet. Our record of estimates for Lexicon Pharmaceuticals begins on Nov 16, 2026, and a quarter can be checked only when we hold an estimate for it from before the company reported.

We started recording estimates on Nov 16, 2026, so quarters that reported before that date cannot be checked.

Our record, one quarter per report
Dec '23left out · currency
Mar '24left out · currency
Jun '24left out · currency
Sep '24left out · currency
Dec '24left out · currency
Mar '25left out · currency
Jun '25left out · currency
Sep '25left out · currency
Dec '25left out · currency
Mar '26left out · currency
Jun '26left out · currency
Sep '26left out · currency
Dec '26not reported yet
Checked so far
None yet
one more every report
Beat expectations
Nothing to count
the first check lands after the next report
Share price reaction
Not held
there is no checked quarter to measure a reaction for
Typical gap vs estimate
Not yet
shown once 4 quarters are checked

Checked against the company's reported figure (GAAP) and the average estimate we recorded the night before its results release. Where analysts' number is on an adjusted basis, we leave the comparison out rather than force it. We started recording estimates for Lexicon Pharmaceuticals on Nov 16, 2026, so earlier quarters cannot be checked, and we never fill them in after the fact.

The Street expects sales to grow −52.2% in FY27. Consensus EPS is a loss at both ends of that step, so there is no EPS growth rate to take apart.

4 analysts publish an EPS estimate for FY26 and 4 publish revenue. Coverage thins with distance: 1 EPS estimate for FY30. Consensus figures are on the Street's basis and filed figures are GAAP; we label the gap, we do not explain it away.Show coverage by yearHide the coverage chart
Analysts by fiscal year · outlined revenue, filled EPS. Amber marks a panel of fewer than 15.
44
FY26E
44
FY27E
65
FY28E
41
FY29E
31
FY30E

The full consensus, year by year

Consensus as of Nov 16, 2026 · filed figures as reported
Revenue · reporting ccy Bfiled · consensus average · band = low to high
−0.00.20.4historyStreet forecastFY22FY25FY30E

Coverage thins with distance: 4 revenue estimates for FY26, 3 for FY30.

Diluted EPS · reporting ccyfiled · consensus average · band = low to high
−0.86−0.290.29historyStreet forecastFY22FY25FY30E

Out-year bands widen as fewer analysts publish: 4 EPS estimates for FY26, 1 for FY30.

Fiscal yearRevenue reporting ccy BYoYEPS reporting ccyYoYEBITDA reporting ccy BNet inc. reporting ccy BShares BAnalysts rev · EPSFwd P/E
FY25Filed · USD0.1—−0.14————as filedn/m
FY26E0.00.0 to 0.0n/ca−0.16−0.17 to −0.14n/ca−0.0−0.10.354 · 4—
FY27E0.00.0 to 0.0▼52.2%−0.21−0.24 to −0.17—−0.1−0.10.354 · 4—
FY28E0.10.0 to 0.1▲324.0%−0.11−0.19 to 0.09—−0.0−0.10.536 · 5—
FY29E0.20.1 to 0.2▲105.7%0.040.02 to 0.06n/cb0.10.00.364 · 1—
FY30E0.30.2 to 0.4▲66.7%0.160.08 to 0.25—0.10.10.363 · 1—

Average estimate with low to high beneath. Amber counts mark thin coverage and thin rows carry an amber rule. Shares = consensus net income ÷ consensus EPS, a direction rather than a decimal. The filed row's last column is today's price over that year's filed EPS, the one trailing multiple in that column. a This step crosses the seam: last year is a filed GAAP actual and this year is a consensus estimate, so the two are not prepared on one basis. b More than a third of the analyst panel changed between these two years, so the difference of the two averages measures the panel rather than the forecast.

These are consensus estimates: what analysts expect the business to earn, not where they think the stock trades. Coverage thins and the low to high band widens in the out-years. Context, not advice.

Analysts' price forecasts and grades are not licensed here. This page shows forward consensus estimates only: 4 EPS estimates for FY26. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.